Menu
The American Heart Association recently reported that cardiovascular disease impacts nearly half of all
American adults. What you might not know is that the risk is exponentially higher within the firefighter community.
Firefighters face many risks on a day-to-day basis, and their profession is recognized as one of the most dangerous in the country. However, firefighter deaths are more likely to stem from cardiac arrest than from any other cause. In fact, a recent study showed that 82 percent of those who died in the line of duty had evidence of coronary heart disease or enlarged hearts – which is contrary to what you may expect given the physical demands of the job.
Despite firefighters being at a higher risk for cardiac-related death, some of the factors that lead them there are similar across the U.S. In fact, the CDC reports that 47 percent of Americans have at least one of the three biggest risk factors, including high cholesterol levels, high blood pressure and smoking. If more people understand these risks, then more people may reach out to their physician when they experience them.
Let’s look at Dennis as an example.
Dennis, a firefighter from Arizona, started experiencing shortness of breath and fatigue during his regular work duties. Initially, his doctor diagnosed him with asthma, but his symptoms persisted. Dennis shrugged it off as part of getting older until a routine physical picked up an irregularity. He was sent to Biltmore Cardiology for a cardiac consult and received a Coronary Computed Tomography Angiogram (CCTA) scan where more than 30 percent stenosis was detected. His physician then ordered the non-invasive HeartFlow Analysis, which showed a significant coronary blockage.
Hear his story in this heartwarming patient video:
Thinking your symptoms of coronary artery disease are signs of something else is not uncommon, however it can be risky to ignore. Over time, the issues intensify, and if not treated, can be deadly. If you are experiencing changes in your health, talk to your physician and know that there are non-invasive solutions available that can help provide clarity.
Dennis is now one of more than 100,000 patients whose lives have been impacted with the HeartFlow Analysis to date. We are proud to have served these patients and the physicians who use it to help guide their diagnosis and treatment decisions.
To better understand risk factors and ways to prioritize your health, read our blog post here. To learn more about The HeartFlow Analysis, click here. See a preview of what a 3D HeartFlow Analysis can look like on mobile here (for iOS only) or desktop here.
HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.